Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | L. Fong, P.M. Forde, J. D. Powderly, J. W. Goldman, J. J. Nemunaitis, J. John Luke, M. D. Hellmann, S. Kummar, R. C. Doebele, D. Mahadevan, S. M. Gadgeel, B. G. M. Hughes, B. Markman, M. J. Riese, J. Brody, L. A. Emens, I. Caffery, R. A. Miller, G. Laport | ||||||||||||
Title | Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/199/AbstView_199_186068.html | ||||||||||||
Abstract Text | J Clin Oncol 35, 2017 (suppl; abstr 3004) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|